Design and synthesis of nanocarriers containing posaconazole against etiological agents of mucormycosis

Panahi, P.; Pourdakan, O.; Zarrinnahad, H.; Mahmoudi, S.; Aghaie, G.; Hosseini, F.; Alemzadeh, S. A.; Malek Raeesi, M.; Mirhendi, H.; Mehravi, B.

doi:10.1101/2025.05.08.652746

bioRxiv · 10.1101/2025.05.08.652746

Design and synthesis of nanocarriers containing posaconazole against etiological agents of mucormycosis

Panahi, P.·Pourdakan, O.·Zarrinnahad, H.·Mahmoudi, S.·Aghaie, G.·Hosseini, F.·Alemzadeh, S. A.·Malek Raeesi, M.·Mirhendi, H.·Mehravi, B.

View original source ↗Export metadata ↓

Abstract

BackgroundPosaconazole is an effective antifungal agent used for many fungal diseases, and its application has grown recently. Posaconazole was studied as a treatment option after the increase in mucormycosis cases linked to COVID-19, and promising results were obtained. However, despite its effectiveness, researchers are looking into new approaches to drug delivery due to problems including restricted bioavailability and short half-life. To address these issues, this project intends to create and synthesize posaconazole-containing liposomes. MethodsIn this study, according to the synthesis of Posaconazole-loaded liposomes, their physical and chemical properties were assessed using SEM, DLS, and FTIR techniques. The drug loading capacity in the nanoparticles, its release in vitro, and the antifungal activity against mucormycosis-causing fungi were evaluated. Finally, the cytotoxicity of these nanoparticles was assessed using the MTT Assay. ResultsThe synthesized nanoparticles were spherical with an average size of approximately 60 nm. The drug loading efficiency was found to be 78.41%. The results indicated that the posaconazole nanoparticles demonstrated a slow and continuous drug release over five days. These nanoparticles demonstrated higher efficacy than posaconazole individually in antifungal tests. Additionally, cytotoxicity tests revealed that, up to a 400 {micro}g/ml concentration, posaconazole-loaded nanoparticles were less toxic than free posaconazole. ConclusionsThese nanoparticles may provide a useful therapeutic option for the treatment of mucormycosis while circumventing the disadvantages of posaconazole due to their improved antifungal activities and decreased toxicity compared to free posaconazole.

Explore related subjects

microbiology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Panahi, P., Pourdakan, O., Zarrinnahad, H., Mahmoudi, S., Aghaie, G., Hosseini, F., Alemzadeh, S. A., Malek Raeesi, M., Mirhendi, H., Mehravi, B.. 2025-05-08. Design and synthesis of nanocarriers containing posaconazole against etiological agents of mucormycosis. https://doi.org/10.1101/2025.05.08.652746

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

A population-scale landscape of the subgingival microbiome reveals divergent routes to periodontal dysbiosis

Periodontitis is an archetypical mucosal inflammatory disease in which microbiome dysbiosis at the tooth-epithelial interface interacts with host genetic and behavioral risk factors to drive immune-mediated tissue destruction. Although subgingival microbiome compositional shifts are thought to parallel disease severity, microbiome variation at the population-level and its relationship to periodontal clinical phenotypes and disease-modifying factors remain poorly defined. Here, we use unsupervised manifold learning to map the compositional landscape of the subgingival microbiome in 1,355 adults spanning periodontal health to severe periodontitis. We identified eight latent microbiome states organized along a branching continuum from eubiosis to dysbiosis. An intermediate microbial configuration marked ecological destabilization and bifurcation into two distinct periodontitis-associated dysbiotic trajectories, distinguished by links to gingival inflammation and smoking. Although the microbiome trajectories broadly tracked periodontal destruction, a minority of individuals showed discordant microbiome-clinical phenotypes, with some individuals with periodontitis retaining otherwise eubiotic microbiomes enriched for low-abundance pathobionts, while some cases of health or mild disease had highly dysbiotic communities, suggesting distinct host susceptibility. Together, these findings define a population-scale ecological landscape of the subgingival microbiome, reveal divergent trajectories to periodontal dysbiosis, and highlight heterogeneity in the relationship between microbial community structure and clinical disease expression.

microbiology↗

bioRxiv2026

Beta-lactam enhancement against methicillin-resistant Staphylococcus aureus by cell wall blockade is autolysis-dependent: a butyrolactone derivative as case in point

Methicillin-resistant Staphylococcus aureus (MRSA) is non-susceptible to beta-lactams. Blockade of cell wall biosynthesis is a potential target for beta-lactam enhancement but requires further investigation. A butyrolactone derivative enhanced beta-lactams against MRSA strains by reducing the availability of D-Ala-D-Ala. Unlike D-cycloserine, it did not inhibit D-Ala-D-Ala ligase (Ddl). Nor did it show an additive or synergistic effect when combined with cycloserine, indicating a unique mechanism for blocking cell wall precursor production that does not involve the traditional Lipid II pathway. Notably, beta-lactam potentiation by our chemical or D-cycloserine was highly dependent on the intrinsic autolytic ability of the tested MRSA strains. Strains that resisted lysis upon Triton X-100 exposure showed a minimal increase in beta-lactam susceptibility, whereas highly autolytic strains showed significant changes in their beta-lactam MICs. We have thus identified autolytic ability as the Achilles Heel in the strategy of targeting cell wall biosynthesis for beta-lactam potentiation.

microbiology↗

bioRxiv2026

Rapid and largely reversible shifts in the canine fecal metabolome during dietary change

Diet can rapidly change the fecal metabolome, but less is known about recovery after the original diet is restored. We used untargeted UPLC-MS metabolomics to analyze 72 fecal samples from nine Pumi dogs during an owner-managed switch from dry food to raw food and back to dry food. Diet phase accounted for a large proportion of variation in both ionization modes. More than 13,000 LC-MS features changed at the first sampling point after the switch to raw food, with a similarly large response after return to dry food. Among features significant in both comparisons, more than 99% changed in opposite directions. At the final sampling point, no positive-mode (ESI+) features and only 13 negative-mode (ESI-) features differed from the second dry-food baseline under the same threshold. BARF-associated patterns persisted in analyses excluding individual dogs and in pedigree-adjusted candidate models, although individual feature effects depended on normalization. Putative metabolites from several biochemical classes differed in their response and recovery. The fecal metabolome therefore changed rapidly and returned largely toward baseline, with differences among dogs.

microbiology↗